Cerebrolysin 1 ml 10 amp

Cerebrolysin (Cerebrolysin)

Each 1 ml of solution contains:

cerebrolysin concentrate (peptide complex) 215.2 mg

Nootropic drug.

Cerebrolysin contains low molecular weight biologically active neuropeptides that penetrate the BBB and directly enter the nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.

Metabolic regulation: the drug Cerebrolysin increases the efficiency of aerobic energy metabolism in the brain, improves intracellular protein synthesis in the developing and aging brain.

Neuroprotection: the drug protects neurons from the damaging effect of lactic acidosis, prevents the formation of free radicals, increases the survivability and prevents neuronal death under conditions of hypoxia and ischemia, reduces the damaging neurotoxic effect of excitatory amino acids (glutamate).

Neurotrophic activity: Cerebrolysin is the only nootropic peptidergic drug with proven neurotrophic activity, similar to the action of natural neuronal growth factors (NGF), but manifested under conditions of peripheral administration.

Functional neuromodulation: the drug has a positive effect on the processes of memorization in cases of impaired cognitive functions.

-Alzheimer’s disease;

– dementia syndrome of various origins;

-chronic cerebrovascular insufficiency;

-ischemic stroke;

-traumatic injuries of the brain and spinal cord;

– mental retardation in children;

– disorders associated with attention deficit in children;

-endogenous depression resistant to antidepressants (as part of complex therapy).

The drug is administered parenterally. The dose and duration of use depend on the nature and severity of the disease, as well as on the age of the patient. A single administration of the drug in a dose of up to 50 ml is possible, however, it is more preferable to carry out a course of treatment.

The recommended course of treatment is daily injections for 10-20 days.

Cerebrolysin is used parenterally in the form of intramuscular injections (up to 5 ml) and intravenous injections (up to 10 ml). The drug in a dose of 10 ml to 50 ml is recommended to be administered only by slow intravenous infusions after dilution with standard infusion solutions. The duration of the infusion is 15 to 60 minutes.

– severe renal failure;

-epileptic status;

-increased sensitivity to the drug.

If the injections are performed too quickly, a feeling of heat, sweating, and dizziness may occur. Therefore, the drug should be administered slowly.

Clinical studies have shown that Cerebrolysin does not affect the ability to drive vehicles and use mechanisms.

From the side of the immune system: very rarely – increased individual sensitivity, allergic reactions.

Mental disorders: rarely – the alleged activation effect is accompanied by excitement, manifested by aggressive behavior, confusion, insomnia.

From the side of the nervous system: rarely – too rapid administration of the drug may lead to dizziness; very rarely – isolated cases of generalized epilepsy and one case of seizures was associated with Cerebrolysin.

From the side of the cardiovascular system: very rarely – too rapid administration of the drug can lead to increased heart rate and arrhythmias.

From the digestive system: very rarely – dyspepsia, diarrhea, constipation, nausea, vomiting; rarely – loss of appetite.

On the part of the skin and subcutaneous tissues: very rarely – skin reactions; rarely – with excessively rapid administration, a sensation of heat, sweating, itching is possible.

General disorders and disorders at the injection site: very rarely – redness, itching.

Store at a temperature not exceeding 25 degrees in a dark place.

The cardboard box contains 10 ampoules of 1 ml and paper instructions.